Literature DB >> 22075208

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

Xiaolin Tu1, Yumie Rhee, Keith W Condon, Nicoletta Bivi, Matthew R Allen, Denise Dwyer, Marina Stolina, Charles H Turner, Alexander G Robling, Lilian I Plotkin, Teresita Bellido.   

Abstract

Sclerostin, the Wnt signaling antagonist encoded by the Sost gene, is secreted by osteocytes and inhibits bone formation by osteoblasts. Mechanical stimulation reduces sclerostin expression, suggesting that osteocytes might coordinate the osteogenic response to mechanical force by locally unleashing Wnt signaling. To investigate whether sclerostin downregulation is a pre-requisite for load-induced bone formation, we conducted experiments in transgenic mice (TG) engineered to maintain high levels of SOST expression during mechanical loading. This was accomplished by introducing a human SOST transgene driven by the 8 kb fragment of the DMP1 promoter that also provided osteocyte specificity of the transgene. Right ulnae were subjected to in vivo cyclic axial loading at equivalent strains for 1 min/day at 2 Hz; left ulnae served as internal controls. Endogenous murine Sost mRNA expression measured 24 h after 1 loading bout was decreased by about 50% in TG and wild type (WT) littermates. In contrast, human SOST, only expressed in TG mice, remained high after loading. Mice were loaded on 3 consecutive days and bone formation was quantified 16 days after initiation of loading. Periosteal bone formation in control ulnae was similar in WT and TG mice. Loading induced the expected strain-dependent increase in bone formation in WT mice, resulting from increases in both mineralizing surface (MS/BS) and mineral apposition rate (MAR). In contrast, load-induced bone formation was reduced by 70-85% in TG mice, due to lower MS/BS and complete inhibition of MAR. Moreover, Wnt target gene expression induced by loading in WT mice was absent in TG mice. Thus, downregulation of Sost/sclerostin in osteocytes is an obligatory step in the mechanotransduction cascade that activates Wnt signaling and directs osteogenesis to where bone is structurally needed.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075208      PMCID: PMC3246572          DOI: 10.1016/j.bone.2011.10.025

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  39 in total

1.  TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro.

Authors:  Julie R Hens; Kimberly M Wilson; Pamela Dann; Xuesong Chen; Mark C Horowitz; John J Wysolmerski
Journal:  J Bone Miner Res       Date:  2005-02-14       Impact factor: 6.741

2.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Authors:  Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

3.  The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Authors:  Kimihiko Sawakami; Alexander G Robling; Minrong Ai; Nathaniel D Pitner; Dawei Liu; Stuart J Warden; Jiliang Li; Peter Maye; David W Rowe; Randall L Duncan; Matthew L Warman; Charles H Turner
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

Review 4.  The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents.

Authors:  H M Frost
Journal:  Bone Miner       Date:  1987-04

5.  Dentin matrix protein 1 gene cis-regulation: use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo.

Authors:  Wuchen Yang; Yongbo Lu; Ivo Kalajzic; Dayong Guo; Marie A Harris; Jelica Gluhak-Heinrich; Shiva Kotha; Lynda F Bonewald; Jian Q Feng; David W Rowe; Charles H Turner; Alexander G Robling; Stephen E Harris
Journal:  J Biol Chem       Date:  2005-02-22       Impact factor: 5.157

6.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Authors:  T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

Review 7.  Function of osteocytes in bone.

Authors:  E M Aarden; E H Burger; P J Nijweide
Journal:  J Cell Biochem       Date:  1994-07       Impact factor: 4.429

8.  Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone.

Authors:  John A Robinson; Moitreyee Chatterjee-Kishore; Paul J Yaworsky; Diane M Cullen; Weiguang Zhao; Christine Li; Yogendra Kharode; Linda Sauter; Philip Babij; Eugene L Brown; Andrew A Hill; Mohammed P Akhter; Mark L Johnson; Robert R Recker; Barry S Komm; Frederick J Bex
Journal:  J Biol Chem       Date:  2006-08-14       Impact factor: 5.157

9.  The P2X7 nucleotide receptor mediates skeletal mechanotransduction.

Authors:  Jiliang Li; Dawei Liu; Hua Zhu Ke; Randall L Duncan; Charles H Turner
Journal:  J Biol Chem       Date:  2005-11-03       Impact factor: 5.157

10.  SOST is a target gene for PTH in bone.

Authors:  Hansjoerg Keller; Michaela Kneissel
Journal:  Bone       Date:  2005-08       Impact factor: 4.398

View more
  197 in total

Review 1.  Signaling pathways affecting skeletal health.

Authors:  Pierre J Marie
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

Review 2.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

3.  Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.

Authors:  W Qin; W Zhao; X Li; Y Peng; L M Harlow; J Li; Y Qin; J Pan; Y Wu; L Ran; H Z Ke; C P Cardozo; W A Bauman
Journal:  Osteoporos Int       Date:  2016-07-20       Impact factor: 4.507

4.  In vivo mechanical loading rapidly activates β-catenin signaling in osteocytes through a prostaglandin mediated mechanism.

Authors:  N Lara-Castillo; N A Kim-Weroha; M A Kamel; B Javaheri; D L Ellies; R E Krumlauf; G Thiagarajan; M L Johnson
Journal:  Bone       Date:  2015-03-30       Impact factor: 4.398

Review 5.  Skeletal changes during and after spaceflight.

Authors:  Laurence Vico; Alan Hargens
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 6.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 7.  The role of estrogen and androgen receptors in bone health and disease.

Authors:  Stavros C Manolagas; Charles A O'Brien; Maria Almeida
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330

8.  Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual.

Authors:  Maria Almeida; Srividhya Iyer; Marta Martin-Millan; Shoshana M Bartell; Li Han; Elena Ambrogini; Melda Onal; Jinhu Xiong; Robert S Weinstein; Robert L Jilka; Charles A O'Brien; Stavros C Manolagas
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 9.  Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2012-11-15       Impact factor: 4.507

10.  The central nervous system (CNS)-independent anti-bone-resorptive activity of muscle contraction and the underlying molecular and cellular signatures.

Authors:  Weiping Qin; Li Sun; Jay Cao; Yuanzhen Peng; Lauren Collier; Yong Wu; Graham Creasey; Jianhua Li; Yiwen Qin; Jonathan Jarvis; William A Bauman; Mone Zaidi; Christopher Cardozo
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.